- Braveheart, Attovia join next wave of biotech IPOs<figure><div><img src="https://imgproxy.divecdn.com/Z8dYUynyAGfRpaERds4uqJPo8FGtQPXgqxIr2sImOmo/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDUxMTE2NzE0LmpwZ…BioPharma Dive · 9d ago↗ source
- Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerAdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment. The round marks one of the largest yet for a r…Endpoints · 9d ago↗ source
- Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside KeytrudaThe Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Par…